Arcus Biosciences, Inc.
RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimabā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$24.59
Price-5.97%
-$1.56
1Y
Price
Market Cap
$3.093b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-207.3%
EBITDA Margin-221.9%
Net Profit Margin-290.2%
Free Cash Flow Margin-207.3%
EBITDA Margin-221.9%
Net Profit Margin-290.2%
Free Cash Flow MarginRevenue
$117m
-52.6%
1y CAGR+21.2%
3y CAGR+17.0%
5y CAGREarnings
-$452m
-28.1%
1y CAGR-15.0%
3y CAGR-15.0%
5y CAGREPS
-$3.93
-19.4%
1y CAGR+0.0%
3y CAGR-2.9%
5y CAGRBook Value
$464m
$924m
Assets$460m
Liabilities$114m
DebtDebt to Assets
12.3%
-0.3x
Debt to EBITDAFree Cash Flow
-$475m
+1.9%
1y CAGR-42.2%
3y CAGR-75.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company